Se espera que el mercado de productos biológicos para el cuidado de heridas de Australia, Corea del Sur, India, Brasil, Emiratos Árabes Unidos e Irán registre una CAGR saludable en el período de pronóstico de 2018 a 2025. El nuevo informe de mercado contiene datos para los años históricos 2016, el año base de cálculo es 2017 y el período de pronóstico es de 2018 a 2025.
Acceda al informe completo: https://databridgemarketresearch.com/reports/customized-wound-care-biologics-market
Segmentación: Mercado de productos biológicos personalizados para el cuidado de heridas
Mercado de productos biológicos personalizados para el cuidado de heridas, por tipo de producto (injertos de piel sintéticos, factores de crecimiento, aloinjertos, xenoinjertos), tipo de herida (heridas, úlceras, quemaduras), usuario final (hospitales, centros de cuidado de heridas, centros ambulatorios, clínicas, centros de salud comunitarios), países (Australia, Corea del Sur, India, Brasil, Emiratos Árabes Unidos e Irán)
Impulsores del mercado de productos biológicos personalizados para el cuidado de heridas
Los factores importantes que impulsan el crecimiento de este mercado consisten en la creciente incidencia de úlceras en los pies, la creciente incidencia de casos de quemaduras, el envejecimiento de la población y la innovación en productos biológicos para el cuidado de heridas que impulsan el crecimiento del mercado de productos biológicos para el cuidado de heridas.
Aumento de casos de úlceras del pie diabético:
Los casos de úlceras del pie diabético han aumentado significativamente a lo largo del tiempo. A continuación, se mencionan algunas estadísticas importantes relacionadas con las úlceras del pie diabético:
- Según la Federación Internacional de Diabetes (FID), en la India alrededor de 69,1 millones de personas padecen diabetes mellitus con una tasa de prevalencia del 9,3%.
- Según Diabetic Foot Australia, 50.000 personas padecen úlcera de pie diabético en Australia y 12.500 sufren amputaciones relacionadas con la diabetes.
- Según la empresa de Servicios de Salud SEHA Abu Dhabi, los EAU registraron una prevalencia de úlceras del pie diabético del 19,3 % en 2015. Entre el 60 % y el 70 % de los pacientes con diabetes desarrollarán neuropatía periférica y el 25 % desarrollarán úlceras del pie.
Con la creciente prevalencia de úlceras del pie, los productos biológicos para el cuidado de heridas han surgido como un nuevo método de tratamiento en expansión. Esto ha brindado a las compañías farmacéuticas la oportunidad de introducir diversos productos en el mercado para satisfacer la creciente demanda de productos biológicos.
Los actores clave de este mercado se centran en colaboraciones para lanzar técnicas innovadoras para el tratamiento de enfermedades crónicas como la diabetes y las úlceras del pie. Por ejemplo, en enero de 2018, Integra LifeSciences (EE. UU.) adquirió Derma Sciences Inc. (EE. UU.). Con esta adquisición, Integra aceleró la estrategia de cuidado avanzado de heridas mediante la incorporación de productos de Derma Sciences basados en tejido amniótico. Asimismo, en febrero de 2017, Mölnlycke Health Care AB (Suecia) adquirió Sundance Solutions (EE. UU.), para el posicionamiento y giro seguro de pacientes, lo que contribuye a la prevención de úlceras por presión. En 2014, Origin, Inc. (EE. UU.) desarrolló una solución patentada de plasma para pacientes con úlceras del pie diabético.
Aumento de la incidencia de casos de quemaduras:
The rising incidences of burn injuries drive the demand of wound care products for curing the burn injuries. According to World Health Organization (WHO), the majority of burn cases occur in low- and middle-income countries and an estimated 180,000 deaths every year are caused by burns. Burn injuries occurs mainly at home and workplace due to lack of required infrastructure such as equipment, resources and personnel required to safe surgery which includes surgical equipment, blood oxygen, water and others. The rising prevalence of burn injuries have resulted in increased demand of wound care biologics products for curing the burn injuries. Some of the important statistics related to burn cases are mentioned below:
- As per WHO in India 1 000 000 people are moderately or severely burnt every year.
- As per national health portal of India, in India around 7 million people suffer from burn injuries each year with 1.4 lakh deaths and 2.4 lakh people suffer with disability.
- As per Health Authority Abu Dhabi The number of Burn cases are 1'074 which 3.3% of overall injuries.
As burn wounds or injuries can be treated by various procedures with the biologics product, the growing incidences of burn cases boosts the growth of the market. Skin grafting procedures is most commonly associated with burn-related inpatient stays. Autografts are used for rapid and permanent closure of full-thickness burns in which a split-thickness skin graft from an uninjured donor site is taken and replaced on the burnt places of the same patient. As per the HCUPnet, 30.0% burn related impatient stay for skin grafting procedures in the U.S. The rising number of burn injuries has increased the number of wounds care biologics used for the treatment, leading to the growth of the wound care biologics market
Rising number of geriatric population:
With our aging population, diseases that compromise skin integrity such as diabetes, skin breakdown with ulcer and chronic wound formation is a frequent consequence. Type of wounds includes pressure ulcers, surgical wounds, venous ulcers, traumatic wounds, arterial wounds, diabetic ulcers and chronic ulcers. There is a strong correlation between age and the incidence of diseases requiring wound products. According to the National Institute of Health, approximately 617 million people are aged and over. The percentage of geriatric population has increased by 17.0% of the world population by 2025. Many countries in Europe and Asia have higher geriatric population. According to World Bank, in 2015, Asia Pacific population is aging faster as compared to any other regions. In 2015, 315.1 million aged population lives in Asia Pacific and this number is expected to increase in the future.
- According to the population census of 2011, the geriatric population was nearly 104 million in India, among them 53 million were females and 51 Million males.
- As per thenews published in Korea the ratio of elderly population over 65 in 2015. 13.1% is expected to reach 40.1% by 2060.
- As per thenews published in Brazil the elderly population is expected to reach 66 million by 2050.
- As per UNESCAP, it is estimated that by 2050 the proportion of elder population is around 8.2% (6.2 million) and would reach nearly 30.0% by 2050.
- As per theAustralian Institute of Health and Welfare in 2016, half of Australia's older people (57.0%, or 2.1 million) were aged 65–74, one-third were aged 74–84 (30.0%, or 1.1 million) and 13.0% were aged 85 and over (487,000)
According to the Population Reference Bureau the average life expectancy is increased from 68 years in 1950 to 79 years in 2013 because the mortality rate has been reduced. In elderly patients the wound healing process is very slow due to low collagen replacement, low elasticity of skin, ageing related diseases like cardiovascular process diabetes and others. Inorder toovercome all these factors new wound care products are required to accelerate the wound healing process in eldery populations considering the ageing related factors which ultimately helps the wound care biologics market to grow.
Major Players: Customized Wound Care Biologics Market
Some of the prominent participants operating in this market are MiMedx, Organogenesis Inc. Integra Life Sciences, ConvaTec Inc., Acell Inc., Allsource, Alphatec Spine, Inc., Amnio Technology, LLC, Amniox Medical, Inc., Anika Therapeutics, Inc., BioHorizons IPH, Inc., Kerecis, Marine Polymer Technologies, Inc., Mölnlycke Health Care AB, Osiris Therapeutics, Inc., Skye Biologics Inc., Smith & Nephew, Solsys Medical, Vericel Corporation, Wright Medical Group N.V. among others.
